David Hill, MD
Critical Care Medicine · Waterbury, CTNPI 1033226584
Payments from drug & device makers
Across 949 payments — averaging $367.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$118K
- GSK$95K
- Sanofi$54K
- Regeneron Healthcare Solutions, Inc.$21K
- Boehringer Ingelheim$14K
- Amphastar Pharmaceuticals, Inc.$9K
- plus $38K from 44 others
Across 9 payments — averaging $100.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$904
What the payments were for
- Consulting fees$18,45010%
- Speaking & faculty fees$151,68479%
- Travel & lodging$3,9272%
- Food & beverage$18,66410%
- Education$3410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$348,977 in reported general payments places this provider in the 95th percentile of 51 critical care medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 240 | $257,922 |
| Breo ElliptaFluticasone/Vilanterol | 223 | $141,033 |
| Dupixent PenDupilumab | 31 | $129,094 |
| Dupixent SyringeDupilumab | 22 | $102,681 |
| Fasenra PenBenralizumab | 17 | $96,143 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 96 | $71,690 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $63,699 |
| SymbicortBudesonide/Formoterol Fumarate | 61 | $21,617 |
| Spiriva RespimatTiotropium Bromide | 28 | $20,578 |
| XolairOmalizumab | 12 | $16,350 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $13,784 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $12,850 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 53 | $12,285 |
| DuleraMometasone/Formoterol | 17 | $11,874 |
| Arnuity ElliptaFluticasone Furoate | 36 | $11,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $94,796 | $495,881626 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $118,378 | $94,698132 claims |
| Boehringer IngelheimSpiriva Respimat | $14,479 | $20,57828 claims |
| Genentech, Inc.Xolair | $1,408 | $16,35012 claims |
| MerckDulera | $39 | $11,87417 claims |
| Mylan Inc.Wixela Inhub | $12 | $7,28253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 critical care medicine providers in Connecticut.
Other critical care medicine in Waterbury
- Richard SilvermanWaterbury$560K
- Robert McDonaldWaterbury$13K
- Ferdinando UrbanoWaterbury$4K
- Elizabeth Mirabile-LevensWaterbury$3K
- Carl SherterWaterbury$1K
- Charis WipflerWaterbury$226
- Seyedtaghi TakyarNew Haven$334K
- Roland El GhazalNew Haven$134K
- Venu VelagapudiNew Haven$110K
- David KaufmanBridgeport$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.